Sofia Masouri1, Irene Stefanaki2, Giorgos Ntritsos3, Katerina P Kypreou2, Eleni Drakaki2, Evangelos Evangelou3,4, Electra Nicolaidou2, Alexandros John Stratigos2, Christina Antoniou2. 1. Department of Dermatology, Andreas Sygros Hospital, University of Athens Medical School, Dragoumi 5, Athens, 161 21, Greece. sofimasouri@yahoo.gr. 2. Department of Dermatology, Andreas Sygros Hospital, University of Athens Medical School, Dragoumi 5, Athens, 161 21, Greece. 3. Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece. 4. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Abstract
INTRODUCTION: Psoriasis is a highly divergent disease with many disease phenotypes, but there are currently no established biomarkers to predict the therapeutic outcomes of systemic treatments. With the introduction of biologic therapies during the last decade and with new treatments constantly emerging, there is a great need to validate biomarkers that have been reported to be associated with treatment response, and to introduce new biomarkers of possible clinical value. METHODS: In the current study, we aimed to investigate the association of psoriasis-related polymorphisms that have previously been reported to effect the anti-tumor necrosis factor alpha (anti-TNF-α) therapies (etanercept, adalimumab, and infliximab) and anti-interleukin-12/23 (anti-IL-12/23) biologic therapy (ustekinumab) in a Greek cohort of psoriasis patients. RESULTS: Rs10484554 in the HLA-C gene showed an association with a good response to anti-TNF-α agents but not to ustekinumab, while rs151823 and rs26653 in the ERAP1 gene showed associations with a good response to anti-IL-12/23 therapy. CONCLUSION: This study is the first in the field of pharmacogenetics in Greek psoriasis patients. Further, larger studies are required to validate our findings and replicate them in various populations.
INTRODUCTION:Psoriasis is a highly divergent disease with many disease phenotypes, but there are currently no established biomarkers to predict the therapeutic outcomes of systemic treatments. With the introduction of biologic therapies during the last decade and with new treatments constantly emerging, there is a great need to validate biomarkers that have been reported to be associated with treatment response, and to introduce new biomarkers of possible clinical value. METHODS: In the current study, we aimed to investigate the association of psoriasis-related polymorphisms that have previously been reported to effect the anti-tumor necrosis factor alpha (anti-TNF-α) therapies (etanercept, adalimumab, and infliximab) and anti-interleukin-12/23 (anti-IL-12/23) biologic therapy (ustekinumab) in a Greek cohort of psoriasispatients. RESULTS:Rs10484554 in the HLA-C gene showed an association with a good response to anti-TNF-α agents but not to ustekinumab, while rs151823 and rs26653 in the ERAP1 gene showed associations with a good response to anti-IL-12/23 therapy. CONCLUSION: This study is the first in the field of pharmacogenetics in Greek psoriasispatients. Further, larger studies are required to validate our findings and replicate them in various populations.
Authors: S Masouri; I Stefanaki; K P Kypreou; E Kodela; G Bethimoutis; G Ntritsos; E Evangelou; A J Stratigos; C Antoniou Journal: Br J Dermatol Date: 2015-06-22 Impact factor: 9.302
Authors: M Talamonti; E Botti; M Galluzzo; M Teoli; G Spallone; M Bavetta; S Chimenti; A Costanzo Journal: Br J Dermatol Date: 2013-08 Impact factor: 9.302
Authors: E Gallo; T Cabaleiro; M Román; G Solano-López; F Abad-Santos; A García-Díez; E Daudén Journal: Br J Dermatol Date: 2013-10 Impact factor: 9.302
Authors: Ying Liu; Cynthia Helms; Wilson Liao; Lisa C Zaba; Shenghui Duan; Jennifer Gardner; Carol Wise; Andrew Miner; M J Malloy; Clive R Pullinger; John P Kane; Scott Saccone; Jane Worthington; Ian Bruce; Pui-Yan Kwok; Alan Menter; James Krueger; Anne Barton; Nancy L Saccone; Anne M Bowcock Journal: PLoS Genet Date: 2008-03-28 Impact factor: 5.917
Authors: N D Loft; L Skov; L Iversen; R Gniadecki; T N Dam; I Brandslund; H J Hoffmann; M R Andersen; R B Dessau; A C Bergmann; N M Andersen; P S Andersen; S Bank; U Vogel; V Andersen Journal: Pharmacogenomics J Date: 2017-07-11 Impact factor: 3.550
Authors: Jonas J W Kuiper; Jessica van Setten; Matthew Devall; Mircea Cretu-Stancu; Sanne Hiddingh; Roel A Ophoff; Tom O A R Missotten; Mirjam van Velthoven; Anneke I Den Hollander; Carel B Hoyng; Edward James; Emma Reeves; Miguel Cordero-Coma; Alejandro Fonollosa; Alfredo Adán; Javier Martín; Bobby P C Koeleman; Joke H de Boer; Sara L Pulit; Ana Márquez; Timothy R D J Radstake Journal: Hum Mol Genet Date: 2018-12-15 Impact factor: 6.150
Authors: Cristina Membrive Jiménez; Cristina Pérez Ramírez; Almudena Sánchez Martín; Sayleth Vieira Maroun; Salvador Antonio Arias Santiago; María Del Carmen Ramírez Tortosa; Alberto Jiménez Morales Journal: J Pers Med Date: 2021-04-12